サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1337841

臨床試験イメージングの世界市場 (～2028年)：ソフトウェア＆サービス・モダリティ・治療分野・エンドユーザー・地域別

Clinical Trial Imaging Market by Software & Service, Modality, Therapeutic Area, End User & Region - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 175 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
臨床試験イメージングの世界市場 (～2028年)：ソフトウェア＆サービス・モダリティ・治療分野・エンドユーザー・地域別
出版日: 2023年08月18日
発行: MarketsandMarkets
ページ情報: 英文 175 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の臨床試験イメージングの市場規模は、予測期間中にCAGR 7.8%で推移し、2023年の13億米ドルから、2028年には19億米ドルの規模に成長すると予測されています。

同市場の拡大は、製薬・バイオテクノロジー分野の拡大、R&D投資の拡大、CROの急増などの要因によって推進されています。一方で、イメージングシステムの導入コストの高さや臨床試験費用の高さが、予測期間中の成長を阻害する主な要因となっています。

サービス＆ソフトウェア別では、サービスの部門が予測期間中の市場で最大の成長率を示す見通しです。同部門の成長は、主にR&D費の増加、臨床試験の拡大、新しい疾患の治療・診断の需要に起因しています。

エンドユーザー別では、医療機器メーカーの部門が最大のCAGRを示す見通しです。これは、医療機器メーカーによるR&D費の増加とR&D活動、医療機器市場の拡大が主な成長要因となっています。

地域別では、アジア太平洋地域が予測期間中に最大のCAGRを記録する見通しです。R&D投資の急増とアジアの新興国への医薬品研究のアウトソーシング志向の高まりが、市場の拡大を推進する極めて重要な要因となっています。

当レポートでは、世界の臨床試験イメージングの市場を調査し、市場概要、市場への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • 特許分析
  • 貿易分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 規制状況
  • 技術分析
  • 臨床試験イメージング：ディスラプティブ技術

第6章 臨床試験イメージング市場：サービス・ソフトウェア別

  • サービス
    • オペレーショナルイメージングサービス
    • 読み取り分析サービス
    • システム&テクニカルサポートサービス
    • 臨床試験設計およびコンサルティングサービス
  • ソフトウェア

第7章 臨床試験イメージング市場：モダリティ別

  • CT
  • MRI
  • 超音波
  • PET
  • X線
  • 心エコー検査
  • その他

第8章 臨床試験イメージング市場：治療分野別

  • 腫瘍
  • 感染症
  • 神経
  • CVS障害
  • 内分泌
  • 免疫疾患
  • その他

第9章 臨床試験イメージング市場：エンドユーザー別

  • 製薬会社
  • バイオテクノロジー企業
  • 医療機器メーカー
  • CRO
  • 学術および政府系研究機関
  • その他

第10章 臨床試験イメージング市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業戦略/有力企業
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • スタートアップ/中小企業の企業評価マトリックス
  • 競合ベンチマーキング
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • ICON PLC.
    • BIOTELEMETRY（PHILIPS）
    • MEDPACE HOLDINGS INC.
    • BIOMEDICAL SYSTEMS CORPORATION（ERT CLINICAL）
    • BIOCLINICA INC.（CLARIO）
    • IXICO PLC.
    • RESONANCE HEALTH ANALYSIS SERVICES（RESONANCE HEALTH）
    • RADIANT SAGE LLC
    • INTRINSIC IMAGING（WCG CLINICAL）
    • CARDIOVASCULAR IMAGING TECHNOLOGIES
  • その他の企業
    • MEDICAL METRICS
    • PRISM CLINICAL IMAGING
    • BOSTON IMAGING CORE LAB
    • ANAGRAM 4 CLINICAL TRIALS
    • LYSCAUT MEDICAL IMAGING COMPANY
    • CALYX GROUP
    • BIOSPECTIVE
    • PROSCAN IMAGING
    • MICRON, INC.
    • IMAGING ENDPOINTS LI LLC.
    • PERSPECTUM
    • PHARMTRACE KLINISCHE ENTWICKLUNG GMBH
    • WORLDCARE CLINICAL
    • MEDIAN TECHNOLOGIES
    • INVICRO. LLC.

第13章 付録

目次
Product Code: MD 4818

The global clinical trial imaging market is projected to reach USD 1.9 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 7.8% during the forecast period. The market's expansion is propelled by factors including the expansion of the pharmaceutical and biotechnology sectors, escalated research and development investments, and the proliferation of Contract Research Organizations (CROs). On the other hand, the high implementation cost of the imaging system and high cost of clinical trials are the major factors hindering the growth of this market during the forecast period.

"The service segment accounted for the highest growth rate in the clinical trial imaging market, by service & software, during the forecast period"

The clinical trial imaging market is segmented into services and software based on product. In 2022, the service segment accounted for the highest growth rate in the clinical trial imaging market. Based on type, the services segment is further classified into operational imaging services, reader analysis services, system & technical support services, and trial design consulting services. The growth of this segment is primarily attributed to the rising R&D spending, expanding clinical trials, and the demand for new disease treatment and diagnostics.

"Medical device manufacturers segment accounted for the highest CAGR"

Based on end user, the clinical trial imaging market is segmented into pharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes, and other end users. In 2022, the medical device manufacturers segment accounted for the highest growth rate. This can be attributed to the increasing R&D expenditure and R&D activities by medical device manufacturers and the expanding medical devices market are the primary growth drivers of the medical device manufacturers segment.

"Asia Pacific: The fastest-growing region clinical trial imaging market"

The global clinical trial imaging market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The surge in research and development investments and the growing inclination towards outsourcing pharmaceutical research to emerging Asian nations are the pivotal catalysts propelling the market's expansion.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Research Coverage:

This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial imaging market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION
    • 1.2.3 GEOGRAPHIC SCOPE
    • 1.2.4 YEARS CONSIDERED
    • 1.2.5 CURRENCY CONSIDERED
  • 1.3 LIMITATIONS
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Key industry insights
      • 2.2.2.3 Breakdown of primary interviews
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 8 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 LIMITATIONS
  • 2.8 CLINICAL TRIAL IMAGING MARKET: RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
    • FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH
  • 4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028
    • FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028
  • 4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2023 VS. 2028
    • FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD
  • 4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028
    • FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028
  • 4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2023 VS. 2028
    • FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP OVER FORECAST PERIOD
  • 4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing R&D spending
      • 5.2.1.2 Growth of pharmaceutical and biotechnology industries
      • 5.2.1.3 Increasing number of CROs
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High implementation cost of imaging systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
      • 5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    • 5.2.4 CHALLENGES
      • 5.2.4.1 High cost of clinical trials
  • 5.3 PRICING ANALYSIS
    • TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022)
  • 5.4 PATENT ANALYSIS
  • 5.5 TRADE ANALYSIS
    • 5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES
    • TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018-2022 (USD MILLION)
    • 5.5.2 TRADE ANALYSIS FOR CT APPARATUSES
    • TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 22 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS
    • TABLE 6 COMPANY ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 CLINICAL TRIAL IMAGING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 DEGREE OF COMPETITION
  • 5.10 PESTLE ANALYSIS
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 NORTH AMERICA
      • 5.11.1.1 US
      • 5.11.1.2 CANADA
    • 5.11.2 EUROPE
    • 5.11.3 ASIA PACIFIC
      • 5.11.3.1 Japan
      • 5.11.3.2 India
      • 5.11.3.3 China
    • 5.11.4 LATIN AMERICA
      • 5.11.4.1 Brazil
      • 5.11.4.2 Mexico
    • 5.11.5 MIDDLE EAST
    • 5.11.6 AFRICA
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES
    • FIGURE 25 REVENUE SHIFT IN CLINICAL TRIAL IMAGING MARKET

6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE

  • 6.1 INTRODUCTION
    • TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
  • 6.2 SERVICES
    • TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.1 OPERATIONAL IMAGING SERVICES
      • 6.2.1.1 Rising number of CROs to drive market
    • TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.2 READ ANALYSIS SERVICES
      • 6.2.2.1 Growing clinical trial activity to support growth
    • TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES
      • 6.2.3.1 Need for continuous technical support to drive market
    • TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.4 TRIAL DESIGN & CONSULTING SERVICES
      • 6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing
    • TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 SOFTWARE
    • 6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO BOOST ADOPTION
    • TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)

7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY

  • 7.1 INTRODUCTION
    • TABLE 16 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • 7.2 CT
    • 7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE ADOPTION
    • TABLE 17 CLINICAL TRIAL IMAGING MARKET FOR CT, BY REGION, 2021-2028
  • 7.3 MRI
    • 7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET
    • TABLE 18 CLINICAL TRIAL IMAGING MARKET FOR MRI, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 ULTRASOUND
    • 7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND
    • TABLE 19 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION, 2021-2028 (USD MILLION)
  • 7.5 PET
    • 7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS TO BOOST ADOPTION
    • TABLE 20 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION, 2021-2028 (USD MILLION)
  • 7.6 X-RAY
    • 7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET
    • TABLE 21 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2021-2028 (USD MILLION)
  • 7.7 ECHOCARDIOGRAPHY
    • 7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST USAGE
    • TABLE 22 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2021-2028 (USD MILLION)
  • 7.8 OTHER MODALITIES
    • TABLE 23 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION, 2021-2028 (USD MILLION)

8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
    • TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 8.2 ONCOLOGY
    • 8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET
    • TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING
    • TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 NEUROLOGY
    • 8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET
    • TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 CVS DISORDERS
    • 8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY
    • TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR CVS DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.6 ENDOCRINOLOGY
    • 8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
    • TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 8.7 IMMUNOLOGICAL DISORDERS
    • 8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS
    • TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.8 OTHER THERAPEUTIC AREAS
    • TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION)

9 CLINICAL TRIAL IMAGING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 32 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 PHARMACEUTICAL COMPANIES
    • 9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET
    • FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012-2026 (USD BILLION)
    • TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 BIOTECHNOLOGY COMPANIES
    • 9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET
    • TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020
    • TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 MEDICAL DEVICE MANUFACTURERS
    • 9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH
    • TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 CROS
    • 9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET
    • TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR CROS, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
    • 9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET
    • TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • 9.7 OTHER END USERS
    • TABLE 39 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

10 CLINICAL TRIAL IMAGING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • TABLE 41 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 44 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Rising biopharma investment to favor market growth
    • TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING
    • TABLE 46 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 47 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 48 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Rising per capita healthcare spending to drive market
    • TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 50 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 51 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 52 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Germany to dominate clinical trial imaging market in Europe
    • TABLE 56 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 57 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 58 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Favorable government initiatives and growing R&D spending to drive market
    • TABLE 59 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 60 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 61 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Presence of leading pharmaceutical companies to support growth
    • TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 63 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 64 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging
    • TABLE 65 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 66 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 67 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing biologics production to support market growth
    • TABLE 68 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 69 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 70 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 71 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 72 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 74 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 China to dominate APAC market throughout forecast period
    • TABLE 78 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 79 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 80 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Rising population and healthcare expenditure to favor market growth
    • TABLE 81 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 82 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 83 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging
    • TABLE 84 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 85 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 86 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 88 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 89 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 90 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 92 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 93 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021-2028 (USD MILLION)
    • TABLE 94 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021-2028 (USD MILLION)
    • TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS
    • TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 97 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX (2022)
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX, 2022
  • 11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022
  • 11.7 COMPETITIVE BENCHMARKING
    • FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS
    • TABLE 98 COMPANY PRODUCT FOOTPRINT
    • TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020-2023)
    • 11.8.2 DEALS
    • TABLE 101 KEY DEALS (2020-2023)

12 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 12.1 KEY PLAYERS
    • 12.1.1 ICON PLC.
    • TABLE 102 ICON PLC.: BUSINESS OVERVIEW
    • FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 BIOTELEMETRY (PHILIPS)
    • TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW
    • FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022)
    • 12.1.3 MEDPACE HOLDINGS INC.
    • TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW
    • FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022)
    • 12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL)
    • TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
    • 12.1.5 BIOCLINICA INC. (CLARIO)
    • TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW
    • 12.1.6 IXICO PLC.
    • TABLE 107 IXICO PLC.: BUSINESS OVERVIEW
    • FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH)
    • TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW
    • FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022)
    • 12.1.8 RADIANT SAGE LLC
    • TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW
    • 12.1.9 INTRINSIC IMAGING (WCG CLINICAL)
    • TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW
    • 12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES
    • TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 MEDICAL METRICS
    • 12.2.2 PRISM CLINICAL IMAGING
    • 12.2.3 BOSTON IMAGING CORE LAB
    • 12.2.4 ANAGRAM 4 CLINICAL TRIALS
    • 12.2.5 LYSCAUT MEDICAL IMAGING COMPANY
    • 12.2.6 CALYX GROUP
    • 12.2.7 BIOSPECTIVE
    • 12.2.8 PROSCAN IMAGING
    • 12.2.9 MICRON, INC.
    • 12.2.10 IMAGING ENDPOINTS LI LLC.
    • 12.2.11 PERSPECTUM
    • 12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH
    • 12.2.13 WORLDCARE CLINICAL
    • 12.2.14 MEDIAN TECHNOLOGIES
    • 12.2.15 INVICRO. LLC.
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS